Track topics on Twitter Track topics that are important to you
Will novel therapies revolutionise the treatment of NASH?
No drug therapies have been approved for patients with nonalcoholic steatohepatitis NASH but how is this set to change within the next five years? Allergan/Tobira's cenicriviroc and Gilead's selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept's obeticholic acid and Genfit's elafibranor. How important are improvements in fibrosis and what do key opinion leaders KOLs believe will impact drug approval prospects? Experts discuss current study designs and endpoints and the challenges facing novel therapies such as longterm safety, cost and diagnosis.
Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic steatohepatitis NASH. 6 US and 6 European KOLs give their insight on two offlabel marketed products and 12 pipeline programmes. KOLs also provide their candid views on the potential for novel mechanisms of action.
Take a tour of the report now:
Combinations ensure [that] you're not just targeting one pathway. Fibrosis is important but so are the inflammatory cascade, insulin resistance and metabolic syndrome. I think that the most promising will be combinations of a primarily antifibrotic agent with an agent that specifically targets the metabolic pathway and insulin resistance. US Key Opinion Leader
This is very developing field, a lot of labs around the world are looking for the ideal noninvasive biomarker for NASH, and I am quite confident that in the next five years we will discover the best one. EU Key Opinion Leader
Sample of therapies covered
Marketed Therapies offlabel
pioglitazone Actos/Glustin; Takeda/Eli Lilly
obeticholic acid Ocaliva; Intercept Pharmaceuticals
elafibranor Genfit Pharmaceuticals
cenicriviroc Allergan/Tobira Therapeutics
emricasan Novartis/Conatus Pharmaceuticals
Aramchol Galmed Pharmaceuticals
semaglutide Novo Nordisk
GRMD02 Galectin Therapeutics
Plus 4 more Download the complete list here >
Sample of KOLs interviewed
KOLs from North America
Professor Scott L. Friedman, MD, Dean for Therapeutic Discovery and Chief of Division of Liver Diseases, The Icahn School of Medicine, Mount Sinai Hospital, New York City
Professor Joel E. Lavine, MD, PhD, Chief of the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Morgan Stanley Children's Hospital and Columbia University Medical Center New York
Dr. Naim Alkhouri, MD, Staff Physician, Digestive Disease Institute and Cleveland Clinic's Children Hospital, Cleveland, Ohio
KOLs from Europe
Professor Vlad Ratziu, MD, PhD, Professor of Hepatology, Universit Pierre et Marie Curie and the Hpital PitiSalptrire Medical School, Paris, France
Professor Dr. Stefano Bellentani, MD, PhD, Gastroenterologist at Azienda USL di Modena, Italy
Professor Phillip Newsome, MD, Professor of Experimental Hepatology, Director of the Centre for Liver Research and Clinical Director of the Birmingham University Stem Cell Centre, UK
Plus 6 more download the full list now >
Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...